Osaka University Graduate School of Medicine has signed a collaborative research agreement with Fuzionaire Diagnostics to develop anticancer radiotherapeutic agents.
More specifically, Osaka's nuclear medicine department will use Fuzionaire Diagnostics' proprietary chemistry alongside the company's affiliate, Fuzionaire Radioisotope Technologies, to produce therapeutic molecules that contain astatine-211, a radioactive isotope that destroys cancer tumors.
Astatine-211 emits alpha particles, which have enough energy to eliminate the primary cells and treat isolated cancer cells, disseminated tumors, micrometastases, and supplement conventional therapies that may leave undetectable tumors that could lead to a recurrence. The first phase of the collaboration will focus on clinical candidates for different oncology indications.
The two companies also plan to evaluate Fuzionaire's fluorine-18 radiochemistry platform, which produces radiopharmaceuticals to identify and localize cancerous tissue in PET images before radiotherapeutic intervention. By doing so, clinicians can determine more appropriate treatment and monitor patient response.
